Galmed Pharma (NASDAQ: GLMD) the first administration of its drug candidate, aramchol, in its proof-of-concept Phase IIa clinical trial for ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE